“The use of synthetic cannabinoid has been increasing throughout the world and has become a major public health problem. The present study aims to investigate the attention, memory, visuospatial and executive functions in individuals with synthetic cannabinoid use disorder and compare the results with findings obtained from individuals with cannabis use disorder and healthy volunteers with no substance use. Impairments in attention, memory, executive and visuospatial functions were identified in individuals with synthetic cannabinoid use disorder and these impairments were found to be significantly greater than in individuals with cannabis use disorder and healthy controls.” https://www.ncbi.nlm.nih.gov/pubmed/29407568 http://www.psy-journal.com/article/S0165-1781(17)30999-X/fulltext]]>
Author Archives: David Worrell
Contribution of spinal 5-HT5A receptors to the antinociceptive effects of systemically administered cannabinoid agonist WIN 55,212-2 and morphine.
“The antinociceptive effects of cannabinoids and opioids have been known for centuries.
Serotonin and its receptors are also known to play important roles in nociception. However, the contribution of spinal 5-HT5A receptors in antinociceptive effects of cannabinoids and opioids has not been studied.
We conducted this study to clarify spinal mechanisms of the actions of the antinociceptive effects of cannabinoids and opioids.
Our findings show that spinal 5-HT5A receptors are involved in the antinociceptive effects of WIN 55,212-2 and morphine.”
https://www.ncbi.nlm.nih.gov/pubmed/29406831
http://www.nrcresearchpress.com/doi/10.1139/cjpp-2017-0567#.Wnr8P2inHrc
Involvement of glycine receptor α1 subunits in cannabinoid-induced analgesia.
“Some cannabinoids have been shown to suppress chronic pain by targeting glycine receptors (GlyRs).
Although cannabinoid potentiation of α3 GlyRs is thought to contribute to cannabinoid-induced analgesia, the role of cannabinoid potentiation of α1 GlyRs in cannabinoid suppression of chronic pain remains unclear.
Here we report that dehydroxylcannabidiol (DH-CBD), a nonpsychoactive cannabinoid, significantly suppresses chronic inflammatory pain caused by noxious heat stimulation.
These findings suggest that spinal α1 GlyR is a potential target for cannabinoid analgesia in chronic inflammatory pain.”
https://www.ncbi.nlm.nih.gov/pubmed/29407767
https://www.sciencedirect.com/science/article/pii/S0028390818300479
“The purpose of this review is to examine and summarize studies assessing the relevance of the endocannabinoid system (ECS) in diabetic kidney disease (DKD).
